Abstract:Background Artemisinin (ART) is an anti-malaria natural compound with a moderate anticancer action. As a metabolite of ART, dihydroartemisinin (DHA) may have stronger anti-colorectal cancer (CRC) bioactivities. However, the effects of DHA and ART on CRC chemoprevention, including adaptive immune regulation, have not been systematically evaluated and compared. Methods Coupled with a newly-established HPLC analytical method, enteric microbiome biotransformation was conducted to identify if the DHA is a gut microbial metabolite of ART. The anti-CRC potential of these compounds was compared using two different human CRC cell lines for cell cycle arrest, apoptotic induction, and anti-inflammation activities. Naive CD4(+) T cells were also obtained for testing the compounds on the differentiation of Treg, Th1 and Th17. Results Using compound extraction and analytical methods, we observed for the first time that ART completely converted into its metabolites by gut microbiome within 24 h, but no DHA was detected. Although ART did not obviously influence cancer cell growth in the concentration tested, DHA very significantly inhibited the cancer cell growth at relatively low concentrations. DHA included G2/M cell cycle arrest via upregulation of cyclin A and apoptosis. Both ART and DHA downregulated the pro-inflammatory cytokine expression. The DHA significantly promoted Treg cell proliferation, while both ART and DHA inhibited Th1 and Th17 cell differentiation. Conclusions As a metabolite of ART, DHA possessed stronger anti-CRC activities. The DHA significantly inhibited cell growth via cell cycle arrest, apoptosis induction and anti-inflammation actions. The adaptive immune regulation is a related mechanism of actions for the observed effects.

Dihydroartemisinin Suppresses Pancreatic Cancer Cells Via a Microrna-Mrna Regulatory Network

Dihydroartemisinin Inhibits Angiogenesis In Pancreatic Cancer By Targeting The Nf-Kappa B Pathway

Dihydroartemisinin Inhibits Growth of Pancreatic Cancer Cells in Vitro and in Vivo

Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway

Dihydroartemisinin Enhances Apo2l/Trail-Mediated Apoptosis in Pancreatic Cancer Cells Via Ros-Mediated Up-Regulation of Death Receptor 5

Growth Inhibitory Effects of Dihydroartemisinin on Pancreatic Cancer Cells: Involvement of Cell Cycle Arrest and Inactivation of Nuclear Factor-Κb

Dihydroartemisinin: A Potential Natural Anticancer Drug

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Dihydroartemisinin Inactivates Nf-Kappa B and Potentiates the Anti-Tumor Effect of Gemcitabine on Pancreatic Cancer Both in Vitro and in Vivo

Progress on the Study of Anti-tumor Mechanisms of Dihydroartemisinin

Dihydroartemisinin Inhibits the Mammalian Target of Rapamycin-Mediated Signaling Pathways in Tumor Cells.

Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling.

Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases

Dihydroartemisinin Exhibits Antitumor Activity Toward Hepatocellular Carcinoma in Vitro and in Vivo.

Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9

Effects of Dihydroartemisinin, a Metabolite of Artemisinin, on Colon Cancer Chemoprevention and Adaptive Immune Regulation

Inhibitory Effect of Dihydroartemisinin on the Proliferation and Migration of Melanoma Cells and Experimental Lung Metastasis From Melanoma in Mice

Dihydroartemisinin induces pyroptosis by promoting the AIM2/caspase-3/DFNA5 axis in breast cancer cells

Histone Deacetylase Inhibitors Facilitate Dihydroartemisinin-Induced Apoptosis In Liver Cancer In Vitro And In Vivo

Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21

Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9 pathway and synergies with capecitabine